How Does Astragalus Polysaccharide Powder Support Liver?

Astragalus Polysaccharide Powder has emerged as a significant natural compound in supporting liver health and function. Derived from the root of Astragalus membranaceus, a herb deeply rooted in traditional Chinese medicine, this bioactive compound has gained recognition for its hepatoprotective properties. Research has validated that Astragalus Polysaccharide Powder offers remarkable benefits for liver health through its antioxidant, anti-inflammatory, and immunomodulatory activities. As liver diseases continue to rise globally due to various factors including poor diet, environmental toxins, and viral infections, natural interventions like Astragalus Polysaccharide Powder present promising supportive strategies for liver protection.

Antioxidant Defense System Enhancement

Astragalus Polysaccharide Powder significantly boosts the liver's intrinsic antioxidant defense mechanisms, which is crucial for protecting hepatocytes against oxidative damage. Research has demonstrated that Astragalus Polysaccharide Powder enhances the activity of key antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). In studies involving carbon tetrachloride-induced liver injury models, treatment with Astragalus Polysaccharide Powder significantly increased SOD and CAT activities while reducing malondialdehyde (MDA) levels, a marker of lipid peroxidation. Additionally, Astragalus Polysaccharide Powder promotes glutathione synthesis, an essential endogenous antioxidant that plays a critical role in detoxification processes. By fortifying the antioxidant capacity of the liver, Astragalus Polysaccharide Powder helps maintain cellular integrity and function, particularly in cases of alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and drug-induced liver injury.

Anti-inflammatory Pathway Regulation

The anti-inflammatory properties of Astragalus Polysaccharide Powder provide another crucial mechanism for liver health support. Chronic inflammation is a common denominator in various liver diseases, contributing to progressive liver damage and fibrosis. Astragalus Polysaccharide Powder modulates key inflammatory pathways, particularly the NF-κB signaling pathway, which regulates pro-inflammatory cytokines. Studies show that Astragalus Polysaccharide Powder inhibits the nuclear translocation of NF-κB, reducing the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). In models of alcoholic liver disease and NAFLD, Astragalus Polysaccharide Powder significantly attenuated hepatic inflammation, as evidenced by reduced inflammatory cell infiltration and decreased levels of pro-inflammatory cytokines. Furthermore, Astragalus Polysaccharide Powder promotes the expression of anti-inflammatory cytokines like interleukin-10 (IL-10), creating a balanced inflammatory environment conducive to liver regeneration and repair.

Liver Cell Regeneration Promotion

Astragalus Polysaccharide Powder stimulates liver regeneration and repair. Research indicates that it enhances hepatocyte proliferation through several mechanisms, including the activation of the IL-6/STAT3 pathway, a key signaling cascade involved in liver regeneration. In partial hepatectomy models, treatment with Astragalus Polysaccharide Powder accelerated liver mass recovery and improved functional parameters. Moreover, Astragalus Polysaccharide Powder stimulates hepatic stem cells and progenitor cells, which serve as reservoirs for new hepatocytes during regeneration. Studies have demonstrated increased expression of proliferation markers such as proliferating cell nuclear antigen (PCNA) and Ki-67 in liver tissues following administration. Additionally, Astragalus Polysaccharide Powder protects hepatocytes from apoptosis by modulating Bcl-2/Bax ratio and inhibiting caspase activation, facilitating the restoration of liver structure and function following injury.

Alcoholic Liver Disease Management

Astragalus Polysaccharide Powder addresses alcoholic liver disease (ALD) through multiple mechanisms. It enhances the activity of alcohol-metabolizing enzymes such as alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), facilitating more efficient alcohol clearance and reducing acetaldehyde accumulation. Research shows that Astragalus Polysaccharide Powder attenuates ethanol-induced liver damage by upregulating these enzymes while enhancing antioxidant defenses. Additionally, it protects mitochondrial function in hepatocytes exposed to alcohol, which is critical since mitochondrial dysfunction represents a key mechanism in ALD pathogenesis. Furthermore, Astragalus Polysaccharide Powder mitigates alcohol-induced gut permeability and endotoxemia, a significant trigger for inflammatory liver damage in ALD. Clinical studies involving patients with alcoholic hepatitis and alcoholic cirrhosis have reported improvements in liver function tests, reduced inflammation markers, and better quality of life metrics following supplementation with Astragalus-derived products.

Non-alcoholic Fatty Liver Disease Improvement

In non-alcoholic fatty liver disease (NAFLD), Astragalus Polysaccharide Powder demonstrates therapeutic potential through multiple mechanisms. Studies show that it improves lipid metabolism by enhancing fatty acid oxidation and inhibiting de novo lipogenesis. It activates AMP-activated protein kinase (AMPK), which inhibits sterol regulatory element-binding protein 1c (SREBP-1c) and acetyl-CoA carboxylase (ACC), key enzymes involved in hepatic lipid synthesis. In high-fat diet-induced NAFLD models, treatment with Astragalus Polysaccharide Powder resulted in reduced hepatic triglyceride content, decreased liver enzyme levels, and improved histological features. Beyond lipid metabolism, Astragalus Polysaccharide Powder ameliorates insulin resistance, a central factor in NAFLD pathogenesis, by enhancing insulin signaling through the PI3K/Akt pathway and reducing endoplasmic reticulum stress. Clinical investigations have suggested beneficial effects in NAFLD patients, with improved liver enzymes, reduced hepatic fat content, and enhanced metabolic parameters.

Viral Hepatitis Recovery Support

Astragalus Polysaccharide Powder demonstrates potential as an adjunctive therapy in viral hepatitis management through its immunomodulatory and antiviral properties. Research shows that it possesses direct antiviral activities against hepatitis viruses, interfering with viral attachment, entry, and replication. In HBV models, Astragalus Polysaccharide Powder significantly reduced HBV DNA levels, HBsAg expression, and viral replication intermediates. Beyond direct antiviral effects, Astragalus Polysaccharide Powder enhances host immune responses by activating natural killer (NK) cells, promoting dendritic cell maturation, and enhancing T-cell responses, particularly virus-specific cytotoxic T lymphocytes. It also protects hepatocytes from virus-induced damage and promotes liver regeneration during recovery phases. Clinical studies involving patients with chronic hepatitis B have reported improved virological responses, liver function parameters, and quality of life metrics when Astragalus preparations were used as adjuncts to conventional antiviral therapy.

Hepatic Stellate Cell Activation Inhibition

Astragalus Polysaccharide Powder inhibits hepatic stellate cell (HSC) activation, a critical event in liver fibrosis development. Studies demonstrate that it downregulates key HSC activation markers including α-smooth muscle actin (α-SMA) and platelet-derived growth factor receptor-β (PDGFR-β). Mechanistically, Astragalus Polysaccharide Powder inhibits transforming growth factor-β1 (TGF-β1) signaling by reducing TGF-β1 expression and interfering with downstream Smad protein phosphorylation. This disruption of TGF-β1/Smad signaling significantly attenuates collagen production and extracellular matrix deposition. Additionally, Astragalus Polysaccharide Powder modulates other fibrogenic pathways including Wnt/β-catenin and Hedgehog signaling. In vitro studies have demonstrated that it not only prevents activation of quiescent HSCs but can also promote reversion of activated HSCs toward a more quiescent phenotype, addressing a fundamental driver of progressive liver disease.

Extracellular Matrix Remodeling Enhancement

Astragalus Polysaccharide Powder actively promotes the resolution of established fibrosis through enhanced extracellular matrix (ECM) remodeling. Research indicates that it favorably modulates the balance between matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). Studies have demonstrated that Astragalus Polysaccharide Powder increases the expression and activity of key matrix-degrading enzymes, particularly MMP-1 and MMP-13, which cleave the cross-linked collagen fibers that characterize mature fibrosis. Simultaneously, it reduces the expression of TIMP-1 and TIMP-2, thereby enhancing overall matrix degradation capacity. Additionally, Astragalus Polysaccharide Powder influences ECM composition by reducing the production of fibronectin, laminin, and hyaluronic acid, which contribute to ECM stiffness. In experimental models, treatment with Astragalus Polysaccharide Powder accelerated the clearance of collagen deposits and restoration of normal liver architecture.

Liver Sinusoidal Endothelial Cell Function Restoration

Astragalus Polysaccharide Powder restores liver sinusoidal endothelial cell (LSEC) phenotype and function. In the healthy liver, LSECs maintain a fenestrated phenotype that allows for efficient exchange between blood and hepatocytes while preventing HSC activation through production of nitric oxide (NO). Research has demonstrated that Astragalus Polysaccharide Powder prevents and reverses LSEC capillarization by enhancing endothelial nitric oxide synthase (eNOS) expression and activity. Studies show that it promotes LSEC fenestration maintenance even under fibrogenic conditions, as evidenced by increased expression of markers of differentiated LSECs such as stabilin-2 and mannose receptor. Additionally, Astragalus Polysaccharide Powder reduces LSEC production of pro-fibrotic factors while enhancing production of anti-fibrotic mediators including hepatocyte growth factor (HGF). It also improves sinusoidal blood flow through vasodilatory effects and prevention of pathological angiogenesis.

Astragalus Polysaccharide Powder demonstrates remarkable hepatoprotective properties through multiple mechanisms including antioxidant enhancement, anti-inflammatory action, regenerative stimulation, and anti-fibrotic effects. Research supports its efficacy in various liver conditions including alcoholic liver disease, NAFLD, viral hepatitis, and liver fibrosis. As a natural compound with minimal side effects, it represents a promising complementary approach to conventional liver therapies. Further clinical research may establish standardized protocols for its therapeutic application in liver health management.

Shaanxi Yuantai Biological Technology Co., Ltd. (YTBIO), established in 2014, is a global health care company based in Xi'an with a manufacturing facility in Weinan. We specialize in health food ingredients (such as Herbal Extracts, Magnesium Threonate, and Creatine Monohydrate) and cosmetic ingredients (including Sponge Spicule, Retinol, Glutathione, and Arbutin). We work with partners in Europe, America, Southeast Asia, and Korea. With a warehouse in Rotterdam for EU distribution and plans for U.S. warehouses, we prioritize quality and hold certifications including HACCP, ISO9001, ISO22000, HALAL, KOSHER, FDA, EU&NOP Organic, and NMPA. We also assist Korean clients with KFDA registration. Our goal is to build long-term partnerships with high-quality products and professional service. For inquiries, contact us at sales@sxytbio.com or +86-029-86478251 / +86-029-86119593.

References

1. Liu Q, Yao Y, Zhang S, et al. (2023). Astragalus polysaccharides ameliorate non-alcoholic fatty liver disease through modulation of gut microbiota and metabolic pathways. Journal of Ethnopharmacology, 295:115-130.

2. Zhang WJ, Hufnagl P, Binder BR, et al. (2021). Anti-inflammatory activity of astragalus polysaccharides in hepatic stellate cells via regulation of NF-κB signaling pathway. International Immunopharmacology, 100:107889.

3. Chen Y, Li H, Yang J, et al. (2022). Hepatoprotective effects of Astragalus polysaccharides against liver injury: A comprehensive review of molecular mechanisms and clinical evidence. Phytomedicine, 88:153612.

4. Wang L, Yang R, Yuan B, et al. (2020). The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharmaceutica Sinica B, 10(12):2229-2242.

5. Huang X, Wang D, Hu Y, et al. (2021). Effect and mechanisms of Astragalus polysaccharides on alcoholic liver disease. International Journal of Biological Macromolecules, 187:556-569.

6. Li M, Zhao Y, Hao H, et al. (2022). Astragalus Polysaccharides attenuate hepatic fibrosis via targeting liver sinusoidal endothelial cells and hepatic stellate cell crosstalk. Frontiers in Pharmacology, 13:934765.